Open Label Study News Today

DelveInsights, Encephalopathy Pipeline Insight 2024 report provides comprehensive insights about 70+ Encephalopathy companies and 70+ pipeline drugs in the Encephalopathy pipeline landscape. It...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International...

RAS-mutated mCRC– In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulti...

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL) and chronic lymphocytic...

Gepotidacin was compared with the combination of ceftriaxone and azithromycin in adolescent and adult patients with uncomplicated urogenital gonorrhea.

– Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older –– Results were more pronounced in the single-arm study in children ages 6 to 11 years, demonstrating the potential that treati...

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the

Gileads Leadership in Metastatic Breast Cancer Showcased With New ...

CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline New,...

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be held December 1-5, 2023, in Orlando, Florida.